probucol has been researched along with Cardiac Failure in 14 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 9.27 | The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study. ( Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018) |
| "In the present study, we examined whether the powerful antioxidant probucol (a clinically used lipid-lowering drug) would attenuate the oxidative stress and energy starvation in experimental model of heart failure (HF) using isoproterenol." | 7.73 | Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat. ( Awad, AS; El-Demerdash, E; El-Hady, AM; Sayed-Ahmed, MM; Taha, RM, 2005) |
| "To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 5.27 | The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study. ( Cong, H; Fu, N; Liang, M; Lin, W; Lu, C; Tian, F; Yang, S; Zhang, J; Zhang, P, 2018) |
| "In the present study, we examined whether the powerful antioxidant probucol (a clinically used lipid-lowering drug) would attenuate the oxidative stress and energy starvation in experimental model of heart failure (HF) using isoproterenol." | 3.73 | Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat. ( Awad, AS; El-Demerdash, E; El-Hady, AM; Sayed-Ahmed, MM; Taha, RM, 2005) |
| "At 3 weeks post-treatment duration, ADR caused heart failure which was prevented by probucol." | 3.70 | Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. ( Belló-Klein, A; Danelisen, I; Li, T; Singal, PK, 2000) |
| "Treatment with probucol was also accompanied by an increase in myocardial GSHPx and superoxide dismutase activities, with a concomitant decrease in lipid peroxidation." | 1.29 | Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. ( Kaul, N; Singal, PK; Siveski-Iliskovic, N, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Farahmand, F | 1 |
| Malik, A | 1 |
| Sharma, A | 1 |
| Bagchi, AK | 1 |
| Singal, PK | 7 |
| Fu, N | 1 |
| Yang, S | 1 |
| Zhang, J | 1 |
| Zhang, P | 1 |
| Liang, M | 1 |
| Cong, H | 1 |
| Lin, W | 1 |
| Tian, F | 1 |
| Lu, C | 1 |
| Fukumoto, Y | 1 |
| El-Demerdash, E | 1 |
| Awad, AS | 1 |
| Taha, RM | 1 |
| El-Hady, AM | 1 |
| Sayed-Ahmed, MM | 1 |
| Betge, S | 1 |
| Lutz, K | 1 |
| Roskos, M | 1 |
| Figulla, HR | 1 |
| Recio-Mayoral, A | 1 |
| Kaski, JC | 1 |
| McMurray, JJ | 1 |
| Horowitz, J | 1 |
| van Veldhuisen, DJ | 1 |
| Remme, WJ | 1 |
| Siveski-Iliskovic, N | 2 |
| Hill, M | 1 |
| Thomas, TP | 1 |
| Li, T | 4 |
| Kaul, N | 1 |
| Iliskovic, N | 2 |
| Morishima, I | 1 |
| Matsui, H | 1 |
| Mukawa, H | 1 |
| Hayashi, K | 1 |
| Toki, Y | 1 |
| Okumura, K | 1 |
| Ito, T | 1 |
| Hayakawa, T | 1 |
| Kumar, D | 2 |
| Danelisen, I | 3 |
| Belló-Klein, A | 1 |
| Kirshenbaum, LA | 1 |
| Sia, YT | 1 |
| Lapointe, N | 1 |
| Parker, TG | 1 |
| Tsoporis, JN | 1 |
| Deschepper, CF | 1 |
| Calderone, A | 1 |
| Pourdjabbar, A | 1 |
| Jasmin, JF | 1 |
| Sarrazin, JF | 1 |
| Liu, P | 1 |
| Adam, A | 1 |
| Butany, J | 1 |
| Rouleau, JL | 1 |
2 reviews available for probucol and Cardiac Failure
| Article | Year |
|---|---|
Combination therapy with probucol prevents adriamycin-induced cardiomyopathy.
Topics: Animals; Antioxidants; Cardiomyopathies; Doxorubicin; Drug Therapy, Combination; Free Radical Scaven | 1995 |
Adriamycin-induced heart failure: mechanism and modulation.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Doxorubicin; Drug Therapy, Comb | 2000 |
1 trial available for probucol and Cardiac Failure
| Article | Year |
|---|---|
The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.
Topics: Aged; Antioxidants; Combined Modality Therapy; Contrast Media; Coronary Disease; Creatinine; Cystati | 2018 |
11 other studies available for probucol and Cardiac Failure
| Article | Year |
|---|---|
Role of oxidative stress versus lipids in monocrotaline-induced pulmonary hypertension and right heart failure.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Catalase; Echocardiography; Glutathione Peroxidase; | 2021 |
[Medicines for dyslipidemia].
Topics: Anion Exchange Resins; Arteriosclerosis; Azetidines; Dyslipidemias; Ezetimibe; Fibric Acids; Heart F | 2012 |
Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat.
Topics: Animals; Energy Metabolism; Heart Failure; Heart Rate; Isoproterenol; Male; Myocardium; Oxidative St | 2005 |
Oral treatment with probucol in a pharmacological dose has no beneficial effects on mortality in chronic ischemic heart failure after large myocardial infarction in rats.
Topics: Administration, Oral; Animals; Antioxidants; Chronic Disease; Collagen; Heart Failure; Male; Myocard | 2007 |
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as | 2007 |
Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats.
Topics: Animals; Antioxidants; Doxorubicin; Glutathione Peroxidase; Heart Failure; Hemodynamics; Lipid Perox | 1994 |
Lipid lowering: an important factor in preventing adriamycin-induced heart failure.
Topics: Animals; Anticholesteremic Agents; Doxorubicin; Glutathione Peroxidase; Heart Failure; Hemodynamics; | 1997 |
Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats.
Topics: Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Antioxidants; Doxorubicin; Heart; He | 1998 |
Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Antineoplastic Agents; Antioxidants; Blotti | 2000 |
Apoptosis in adriamycin cardiomyopathy and its modulation by probucol.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cardiomyopathies; Caspase 3; | 2001 |
Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat.
Topics: Animals; Antioxidants; Apoptosis; Atrial Natriuretic Factor; Chronic Disease; Disease Models, Animal | 2002 |